M
Mario Boccadoro
Researcher at University of Turin
Publications - 670
Citations - 39049
Mario Boccadoro is an academic researcher from University of Turin. The author has contributed to research in topics: Multiple myeloma & Lenalidomide. The author has an hindex of 83, co-authored 638 publications receiving 34589 citations. Previous affiliations of Mario Boccadoro include Mount Sinai Hospital.
Papers
More filters
Journal ArticleDOI
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis
Stefania Oliva,M.T. Petrucci,Vittorio Montefusco,Concetta Conticello,Pellegrino Musto,Lucio Catalano,Andrea Evangelista,Stefano Spada,Philip Campbell,Roberto Ria,Marco Salvini,Massimo Offidani,A. M. Carella,Paola Omedè,Anna Marina Liberati,Rosella Troia,A. M. Cafro,Alessandra Malfitano,A. Falcone,Tommaso Caravita,Francesca Patriarca,Arnon Nagler,Andrew Spencer,Roman Hájek,Antonio Palumbo,Mario Boccadoro +25 more
TL;DR: The role of upfront ASCT as the standard approach for all young myeloma patients is confirmed, and the impact of salvage ASCT at first relapse in patients who received upfront CC+R is still effectively rescued.
Journal ArticleDOI
Upfront Single Versus Double Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial)
Michele Cavo,Maria Teresa Petrucci,Francesco Di Raimondo,Elena Zamagni,Barbara Gamberi,Claudia Crippa,Giulia Marzocchi,Mariella Grasso,Stelvio Ballanti,Donatella Vincelli,Paola Tacchetti,Massimo Offidani,Gianpietro Semenzato,Anna Marina Liberati,Anna Pascarella,Giulia Benevolo,Rossella Troia,Angelo D. Palmas,Nicola Cantore,Rita Rizzi,Fortunato Morabito,Mario Boccadoro,Pieter Sonneveld +22 more
TL;DR: The role of single vs double autologous stem cell transplantation in patients with newly diagnosed (ND) multiple myeloma (MM) needs to be prospectively investigated in the novel agent era and a high-risk cytogenetic profile was observed in 26% of evaluable patients who were randomized to ASCT-1 and in 21% of those randomly assigned to AS CT-2.
Journal ArticleDOI
Melphalan, Prednisone, and Lenalidomide for Newly Diagnosed Myeloma: Kinetics of Neutropenia and Thrombocytopenia and Time-to-Event Results
Antonio Palumbo,Patrizia Falco,Antonietta Falcone,Giulia Benevolo,Letizia Canepa,Alessandra Larocca,Valeria Magarotto,Alessandro Gozzetti,Annalisa Luraschi,Fortunato Morabito,Andrea Nozza,Robert Knight,Jerome B. Zeldis,Mario Boccadoro,Maria Teresa Petrucci +14 more
TL;DR: MPR is a promising regimen with manageable hematologic toxicity with significant antimyeloma activity in patients with untreated multiple myeloma.
Journal ArticleDOI
PCR-Detectable Nonneoplastic Bcl-2/IgH Rearrangements Are Common in Normal Subjects and Cancer Patients at Diagnosis but Rare in Subjects Treated With Chemotherapy
Marco Ladetto,Daniela Drandi,Mara Compagno,Monica Astolfi,Federica Volpato,Claudia Voena,Anna Novarino,Berardino Pollio,Alfredo Addeo,Irene Ricca,Patrizia Falco,Federica Cavallo,Sonia Vallet,Paolo Corradini,Alessandro Pileri,Giacomo Tamponi,Antonio Palumbo,Oscar Bertetto,Mario Boccadoro,Corrado Tarella +19 more
TL;DR: The low incidence of nonneoplastic Bcl-2/IgH rearrangements following chemotherapy provides further evidence of the prognostic role of persistent PCR-positivity in the posttreatment molecular follow-up of follicular lymphoma patients.
Journal ArticleDOI
Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma.
Antonio Palumbo,Alessandra Larocca,Patrizia Falco,Grazia Sanpaolo,A. Falcone,Federico,Letizia Canepa,Monica Crugnola,Maurizio Genuardi,Magarotto,M.T. Petrucci,Mario Boccadoro +11 more
TL;DR: RMPT is an active salvage therapy with good efficacy and manageable side effects in patients with relapsed/refractory multiple myeloma and represents the basis for larger phase III randomized trials.